These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Pogue JM; Kaye KS; Veve MP; Patel TS; Gerlach AT; Davis SL; Puzniak LA; File TM; Olson S; Dhar S; Bonomo RA; Perez F Clin Infect Dis; 2020 Jul; 71(2):304-310. PubMed ID: 31545346 [TBL] [Abstract][Full Text] [Related]
4. Experience With Ceftolozane-Tazobactam for the Treatment of Serious Bosaeed M; Ahmad A; Alali A; Mahmoud E; Alswidan L; Alsaedy A; Aljuhani S; Alalwan B; Alshamrani M; Alothman A Infect Dis (Auckl); 2020; 13():1178633720905977. PubMed ID: 32110036 [TBL] [Abstract][Full Text] [Related]
5. Activity of ceftolozane/tazobactam against a collection of Pseudomonas aeruginosa isolates from bloodstream infections in Australia. Henderson A; Tan E; McCarthy KL; Paterson DL Pathology; 2018 Dec; 50(7):748-752. PubMed ID: 30392710 [TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA. Tran TT; Cabrera NL; Gonzales-Luna AJ; Carlson TJ; Alnezary F; Miller WR; Sakurai A; Dinh AQ; Rydell K; Rios R; Diaz L; Hanson BM; Munita JM; Pedroza C; Shelburne SA; Aitken SL; Garey KW; Dillon R; Puzniak L; Arias CA JAC Antimicrob Resist; 2023 Feb; 5(1):dlac131. PubMed ID: 36601551 [TBL] [Abstract][Full Text] [Related]
7. Treatment of multidrug-resistant Pseudomonas aeruginosa bacteremia using ceftolozane-tazobactam-based or colistin-based antibiotic regimens: A multicenter retrospective study. Hakeam HA; Askar G; Al Sulaiman K; Mansour R; Al Qahtani MM; Abbara D; Aldhayyan N; Dyab N; Afaneh L; Islami M; Al Duhailib Z J Infect Public Health; 2022 Oct; 15(10):1081-1088. PubMed ID: 36113401 [TBL] [Abstract][Full Text] [Related]
8. Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance. Haidar G; Philips NJ; Shields RK; Snyder D; Cheng S; Potoski BA; Doi Y; Hao B; Press EG; Cooper VS; Clancy CJ; Nguyen MH Clin Infect Dis; 2017 Jul; 65(1):110-120. PubMed ID: 29017262 [TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823 [TBL] [Abstract][Full Text] [Related]
10. A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Hart DE; Gallagher JC; Puzniak LA; Hirsch EB; Open Forum Infect Dis; 2021 Mar; 8(3):ofab089. PubMed ID: 33796600 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497 [TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088 [TBL] [Abstract][Full Text] [Related]
13. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015. Shortridge D; Castanheira M; Pfaller MA; Flamm RK Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483953 [TBL] [Abstract][Full Text] [Related]
14. Ceftolozane-tazobactam for the treatment of multidrug-resistant Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260 [TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909 [TBL] [Abstract][Full Text] [Related]
16. Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazobactam Susceptibility. Shortridge D; Pfaller MA; Castanheira M; Flamm RK Microb Drug Resist; 2018 Jun; 24(5):563-577. PubMed ID: 29039729 [TBL] [Abstract][Full Text] [Related]
17. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa. Vickery SB; McClain D; Wargo KA Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066 [TBL] [Abstract][Full Text] [Related]
18. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018. Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763 [TBL] [Abstract][Full Text] [Related]
19. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073 [TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS; Farrell DJ; Flamm RK; Jones RN J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]